Literature DB >> 6450718

Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

B J Potter, D J Brown, A Watson, D P Jewell.   

Abstract

The serum concentrations of the complement inactivators C1INH, C3bINA and beta 1H have been determined in patients with ulcerative colitis and Crohn's disease and their correlation with C3 and properdin factor B examined. The incidence of immunoconglutinins (1K) in these patients was investigated. Raised serum concentrations of C1INH and C3bINA have been found in patients with active disease, but no significant alteration was found in serum concentration of beta 1H. An increasing incidence of positive 1K titres was found with increased length of disease history. These results suggest continuing complement activation in these diseases.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6450718      PMCID： PMC1419393          DOI： 10.1136/gut.21.12.1030

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  23 in total

1.  Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa.

Authors:  J Ballard; M Shiner
Journal:  Lancet       Date:  1974-05-25       Impact factor: 79.321

2.  Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.

Authors:  W F Doe; C C Booth; D L Brown
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

3.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

4.  Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.

Authors:  P F Kohler; R Ten Bensel
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

5.  Decreased properdin activity in acute glomerulonephritis.

Authors:  H Gewurz; R J Pickering; G Naff; R Snyderman; S E Mergenhagen; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

6.  Positive epinephrine skin test for "circulating endotoxin" in inflammatory disease of the intestine.

Authors:  G E Bowen; J B Kirsner
Journal:  Am J Clin Pathol       Date:  1965-12       Impact factor: 2.493

7.  Proceedings: Serum complement components C3 and C4 in inflammatory bowel disease.

Authors:  M Ward; M A Eastwood
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

8.  Humoral immune system activity in inflammatory bowel disease.

Authors:  P Teisberg; E Gjone
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

9.  Short-term course and prognosis of Crohn's disease.

Authors:  F T De Dombal; I L Burton; S E Clamp; J C Goligher
Journal:  Gut       Date:  1974-06       Impact factor: 23.059

10.  Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components.

Authors:  H Gewurz; H S Shin; S E Mergenhagen
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307
View more
  9 in total

Review 1.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement.

Authors:  J Elmgreen; H Both; V Binder
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

3.  Subnormal activation of phagocytes by complement in chronic inflammatory bowel disease? Neutrophil chemotaxis to complement split product C5a.

Authors:  J Elmgreen
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

4.  Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.

Authors:  O H Nielsen; I Ahnfelt-Rønne; J Elmgreen
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

5.  Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.

Authors:  Lu Liu; Dan Pu; Dandan Wang; Muhan Zhang; Chuan Zhou; Zhe Zhang; Baisui Feng
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

6.  A cross-ethnic survey of CFB and SLC44A4, Indian ulcerative colitis GWAS hits, underscores their potential role in disease susceptibility.

Authors:  Aditi Gupta; Garima Juyal; Ajit Sood; Vandana Midha; Keiko Yamazaki; Arnau Vich Vila; Motohiro Esaki; Toshiyuki Matsui; Atsushi Takahashi; Michiaki Kubo; Rinse K Weersma; B K Thelma
Journal:  Eur J Hum Genet       Date:  2016-10-19       Impact factor: 4.246

7.  Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Authors:  Vasil V Vasilev; Remi Noe; Marie-Agnes Dragon-Durey; Sophie Chauvet; Valentin J Lazarov; Boriana P Deliyska; Veronique Fremeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

8.  Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma.

Authors:  Chenglu He; Ya Li; Ruixian Zhang; Jing Chen; Xingxing Feng; Yong Duan
Journal:  Oncol Lett       Date:  2021-04-19       Impact factor: 2.967

Review 9.  Autoantibodies Against C3b-Functional Consequences and Disease Relevance.

Authors:  Vasil V Vasilev; Maria Radanova; Valentin J Lazarov; Marie-Agnes Dragon-Durey; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.